Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

EpiVax-RiskAssessment

More Like This

Biognosys Presents Technological Innovations and Scientific Progress to Make the Proteome Actionable for Life Science Research at the HUPO 2023 World Congress

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

PR Newswire associated0

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

ACCESSWIRE associated1

Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling

ACCESSWIRE logo

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

PR Newswire associated0

Pioneering the Next Frontier: ArisGlobal Unveils Cutting-Edge Safety & Regulatory Product Offerings Powered by Generative AI

IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma

PR Newswire associated0

Newest Version of LifeSphere® Regulatory Platform Allows Organizations to Leverage Latest GenAI Technology